Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study

Doyle, Adam; Marsh, Philip; Gill, R. S.; Rodov, Marcia; Mohsen, Waled; Varma, Poornima; Hong, Thai; Strasser, Simone I.; Bell, Sally; Nicoll, Amanda; Lubel, John S; Gow, Paul J; Fink, Michael A; Roberts, Stuart K.; Kemp, William; Kronborg, Ian; Arachchi, Niranjan; Knight, Virginia; Dev, Anouk

doi:10.3109/00365521.2016.1166518

Cited by 10 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multivariate analysis showed that indicators of liver function seemed to have a greater impact on prognosis than tumor burden, distribution, and tumor thrombus levels. It was confirmed by other researches that attention should be not only paid to tumorrelated conditions, but also to the liver function of patients (26,27).…”

Section: Discussionmentioning

confidence: 58%

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study

Mei

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Macroscopic vascular invasion (MVI) commonly occurs in patients with advanced hepatocellular carcinoma (HCC) for which resection and sorafenib are the common therapies prescribed. Here, we aimed to compare the survival outcomes of these two therapies in HCC patients with MVI. Methods: In total, 496 patients diagnosed with HCC and MVI without extrahepatic metastasis, treated with resection (resection-based group, n = 388) and sorafenib (sorafenib-based group, n = 108) were included in this study. A one-to-one propensity score-matching analysis (PSM) was performed to minimize the effect of potential confounders. Results: The median OS in the resection-and sorafenib-based group was 20.7 months (95% CI: 16.9-24.5) and 11.6 months (95% CI: 8.4-14.9) (p < 0.001), respectively. The median PFS was 4.7 months (95% CI: 3.8-5.5) in the resection-based group and 4.4 months (95% CI: 3.6-5.2) in the sorafenib-based group (p < 0.001). After PSM, 72 patients from each group were matched. The median OS was 27.2 months (95% CI: 16.4-38.0) in the resection-based group and 13.0 months (95% CI: 9.6-16.3) in the sorafenib-based group (p < 0.001). The median PFS was 5.3 months (95% CI: 3.2-7.4) in the resection-based group and 4.8 months (95% CI: 3.6-6.0) in the sorafenib-based group (p = 0.061). Conclusion: Findings from this study showed that, compared with sorafenib-based treatment, surgical resection might be associated with better survival benefits to HCC patients with MVI.

show abstract

Section: Discussionmentioning

confidence: 58%

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study

Mei

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Diarrhea may be due to the blockage of EGFR, which is highly expressed in intestinal epithelium, and partly to the inflammatory reaction of the gut to sorafenib [46]. Few studies have reported a significant correlation between diarrhea and sorafenib efficacy; but from available data it seems that the occurrence of diarrhea is associated with improved OS [47,48] and longer TTP [49]. In our series, diarrhea occurred in 26.9% of patients and was mild in most cases.…”

Section: Validation Of the Scoring Systemmentioning

confidence: 58%

Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Sorafenib has been shown to improve survival in the treatment of HCC. However, only a limited number of patients have responded beneficially 3 . Prognosis of HCC remains poor, and HCC-related mortality is high 4 .…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells

Wang¹,

Yang²,

Yu³

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Purpose The aim of this study was to evaluate the clinical response of immunotherapy with dendritic cell-cytotoxic T lymphocytes (DC-CTLs) in patients with hepatocellular carcinoma (HCC).Method Sixty-eight patients with a confirmed diagnosis of HCC and who received follow-up until December 2015 were enrolled. We measured immune phenotypes of DCs and activated T cells using flow cytometry and clinical indexes using an electrochemiluminescence method.Results DCs exhibited up-regulation of the maturation markers CD83, CD80, CD11c, and CD86 on day8. Levels of IFN-γ and TNF-α were higher in the DCs pulsed with tumor-associated antigens (TAAs) than in DCs with a non-proliferative recombinant adenovirus. The percentage of regulatory T cells (Tregs) decreased in patients after DC-CTLs therapy. In addition, serum levels of AFP, AFP-L3, ALT, and CA19-9 were significantly reduced in these patients. Quality of life was improved, especially on physical functioning scales. Median overall survival (OS) and progression-free survival (PFS) were 8.2 months and 4.3 months, respectively, for the control group and 12.8 months and 9 months, respectively, for the DC-CTL group. Patients treated with DC-CTLs therapy showed a statistically significant PFS and OS curve (OS: p=0.016; PFS: p<0.0001). In addition, no serious adverse reactions were observed.Conclusion This study indicated that Tregs, as well as serum levels of AFP, AFP-L3, ALT, and CA19-9, which were correlated with a poor prognosis, decreased after DC-CTL treatments. The OS, PFS and the quality of life of HCC patients partially improved.

show abstract

Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study

Cited by 10 publications

References 21 publications

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study

Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma

Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells

Contact Info

Product

Resources

About